Tobradex (Tobramycin/Dexamethasone) Patent Expiration, LOE Window & CMS Spending

Tobradex (Tobramycin/Dexamethasone) by Sandoz: Off-Patent Genericized (AB Competition), 2 AB generics, $21.1M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSandoz
FDA Application & PathwayN050592 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$21.1M
2024 Medicare Part D Spend$15.5M
2024 Medicaid Spend$5.6M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 24.4% 2-yr change)